Hypothetically, the use of autologous iPSC-derived myogenic progenitor cells in which the DYSTROPHIN gene is corrected by CRISPR/Cas9 technology could regenerate muscles in patients with DMD [118]. Here, DMD is linked to Duchenne muscular dystrophy.